

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

#### Protocol summary

##### Summary

Aim: Evaluation of intravitreal injection of Bevacizumab for treatment of chronic central serous chorioretinopathy . Design: Prospective, Consecutive , non randomized Clinical Trial. Participants and Intervention: 15 patient of Acute Central Serous Chorioretinopathy That is not Anatomically improved for more than 4-months (Persistent Macular Sub-Sensory Retinal Fluid ) will receive 0.1 cc/2.5 mg of Avastin Intravitreally . Before Injection , The diagnosis should be Confirmed by Ocular Coherent Tomography (OCT) and Fluorescein Angiography (FFA) . Also all the Patients will be examined by another ophthalmologist (Supervisor of The Study ) and The diagnosis of the Chronic Central Serous Chorioretinopathy should be Confirmed by him.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201202198983N1**  
Registration date: **2012-03-17, 1390/12/27**  
Registration timing: **registered\_while\_recruiting**

Last update:

Update count: **0**

##### Registration date

2012-03-17, 1390/12/27

##### Registrant information

###### Name

Mohammad rasoul Sabouri

###### Name of organization / entity

Guilan University of Medical Sciences

###### Country

Iran (Islamic Republic of)

###### Phone

+98 13 1223 6886

##### Email address

sabouri@gums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Guilan university of medical sciences

##### Expected recruitment start date

2012-02-19, 1390/11/30

##### Expected recruitment end date

2014-02-19, 1392/11/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

##### Public title

Evaluation of Intravitreal injection of Bevacizumab for treatment of Chronic Central Serous Chorioretinopathy

##### Purpose

Treatment

##### Inclusion/Exclusion criteria

Inclusion criteria : 1- patient by Acute Central Serous Chorioretinopathy for more than 4-months. 2- Confirmation of The Chronic Central Serous Chorioretinopathy by Ocular Coherent Tomography (OCT) and Fluorescein Angiography (FFA) . 3- confirmation of the Disease by Supervisor of Study. Exclusion criteria: 1- Chronic Central Serous Chorioretinopathy more than 2 years. 2- History of Treatment by any type of Laser. 3- History of Thromboembolic Disease Like Myocardial Infarction and Cerebro Vascular accident. 4- History of Treatment by Intravitreal Avastin during 2 months ago. 5- any systemic Disease that need Oral Corticosteroid Therapy. 6- un - Controlled Glaucoma 7- Pregnancy 8- Lack

of agreement by Patient for periodic Follow up during study.

**Age**

From **20 years** old to **50 years** old

**Gender**

Both

**Phase**

N/A

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **15**

**Randomization (investigator's opinion)**

N/A

**Randomization description****Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Single

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Guilan University of Medical Sciences

**Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

**City**

Rasht

**Postal code**

4139637459

**Approval date**

2012-01-11, 1390/10/21

**Ethics committee reference number**

1901130501

**Health conditions studied****1****Description of health condition studied**

chronic central serous chorioretinopathy

**ICD-10 code**

VII

**ICD-10 code description**

Disease of the eye and adnexa

**Primary outcomes****1****Description**

Vision Improvement

**Timepoint**

every 6 to 8 weeks until 6 month

**Method of measurement**

Snellen Chart

**2****Description**

Anatomical Improvement

**Timepoint**

every 6 to 8 weeks until 6 month

**Method of measurement**

Clinical exam and OCT

**Secondary outcomes****1****Description**

central thickness of retin

**Timepoint**

per 6-8 weeks till 6 month

**Method of measurement**

with OCT.If in the first examination( by OCT) after weeks 6 to 8 ,at least 10 % reduction in the central macular thickness occur,the patient will be periodically follow,if not ,the patient will be omitted.

**Intervention groups****1****Description**

In the operating room, under local anesthesia, and MAC and sterile condition by using 10% & 5% Betadine for periorbital and culdesac area and prep & drape and insertion of speculum and after 0.1 cc AC-tap ,0.1cc/2.5 mg Bevacizumab(Avastin) will be injected through superior / inferior temporal quadran 3.5 mm away from limbus using 30- guage needle

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Amiralmomenin Hospital

**Full name of responsible person**

dr mohammad rasoul sabouri

**Street address**

17 shahrivar street

**City**

Rasht

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Guilan University of Medical Sciences, Pro-vice-chancellor for research

**Full name of responsible person**

Susan Komaie

**Street address**

Pro-vice Chancellor for Research, Namjoo Ave, Mellat St, Rasht, Guilan, Iran

**City**

Rasht

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Guilan University of Medical Sciences, Pro-vice-chancellor for research

**Proportion provided by this source**

100

**Public or private sector**

*empty*

**Domestic or foreign origin**

*empty*

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

*empty*

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Guilan University of Medical Sciences

**Full name of responsible person**

Dr Mohammad Rasoul Sabouri

**Position**

Assistant Professor

**Other areas of specialty/work****Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

**City**

Rasht

**Postal code****Phone**

+98 13 1223 6886

**Fax****Email**

sabouri@gums.ac.ir

**Web page address**

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Guilan University of Medical Sciences

**Full name of responsible person**

Dr Mohammad Rasoul Sabouri

**Position**

Assistant professor

**Other areas of specialty/work****Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

**City**

Rasht

**Postal code****Phone**

+98 13 1223 6886

**Fax****Email**

sabouri@gums.ac.ir

**Web page address**

## Person responsible for updating data

**Contact****Name of organization / entity**

Guilan University of Medical Sciences

**Full name of responsible person**

Dr Mohammad Rasoul Sabouri

**Position**

Assistant Professor

**Other areas of specialty/work****Street address**

Amiralmomenin Hospital, 17 Shahrivar Ave, Rasht, Guilan, Iran

**City**

Rasht

**Postal code**

0098

**Phone**

+98 13 1223 6886

**Fax**

+98 13 1223 6886

**Email**

sabouri@gums.ac.ir

**Web page address**

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*